Judd Moul(@JuddMoul) 's Twitter Profileg
Judd Moul

@JuddMoul

James H Semans Professor of Urology & Professor of Anesthesia , DukeUniversity, Urologic Oncologist, Duke Cancer Institute. Focus on Prostate Cancer MC,USA(ret)

ID:2881260575

linkhttp://dukehealth.org calendar_today17-11-2014 16:16:54

6,9K Tweets

3,0K Followers

1,2K Following

Follow People
UroToday.com(@urotoday) 's Twitter Profile Photo

Biochemical recurrence in patients with after primary definitive therapy: Next-generation imaging and treatment based on risk stratification. with Judd Moul Duke Cancer and Neal Shore, MD, FACS CURC on UroToday > bit.ly/3T8cjea

Biochemical recurrence in patients with #ProstateCancer after primary definitive therapy: Next-generation imaging and treatment based on risk stratification. #BeyondTheAbstract with @JuddMoul @DukeCancer and Neal Shore, MD, FACS @CURCMB on UroToday > bit.ly/3T8cjea
account_circle
Judd Moul(@JuddMoul) 's Twitter Profile Photo

Kudos to my long time friend and colleague Dr Axel Heidenreich from Cologne and my Duke Urology uro onc partner Dr Deborah Kaye for great course on PSMA PET.

#AUA2024 Kudos to my long time friend and colleague Dr Axel Heidenreich from Cologne and my @DukeUrology uro onc partner Dr Deborah Kaye for great course on PSMA PET.
account_circle
Judd Moul(@JuddMoul) 's Twitter Profile Photo

Truly an honor to share stage with this esteemed faculty and especially Dr Chris Logothetis who announced from the stage that this was his >>40 years in our field. John W. Davis, MD
DCI Center for Prostate & Urologic Cancers

Truly an honor to share stage with this esteemed faculty and especially Dr Chris Logothetis who announced from the stage that this was his >>40 years in our field. @jdhdavis @DukeGUCancer
account_circle
John W. Davis, MD(@jdhdavis) 's Twitter Profile Photo

Good morning. The International Prostate Forum runs 7:30 to noon today with a lunch to follow. We will work through 4 key disease spaces from advanced to screening and prevention. Hemisfair C1.

Good morning. The International Prostate Forum runs 7:30 to noon today with a lunch to follow. We will work through 4 key disease spaces from advanced to screening and prevention. Hemisfair C1.
account_circle
Badar M. Mian, MD(@BadarMian1) 's Twitter Profile Photo

πŸ“’πŸ“’πŸ“’ Hot off the web:
Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the ProBE-PC RCT
auajournals.org/doi/full/10.10…

- 840 men randomized
- URONAV fusion for TP & TR
- Targeted plus systematic biopsy
- No difference

πŸ“’πŸ“’πŸ“’ Hot off the web: Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the ProBE-PC RCT auajournals.org/doi/full/10.10… - 840 men randomized - URONAV fusion for TP & TR - Targeted plus systematic biopsy - No difference
account_circle
John Rewcastle, PhD(@rewcastle_john) 's Twitter Profile Photo

Bilateral grade group 2 disease is common: > 50% of theoretical focal candidates had disease not suitable for focal therapy.

Bilateral grade group 2 disease is common: > 50% of theoretical focal candidates had disease not suitable for focal therapy. #AUA24
account_circle
Judd Moul(@JuddMoul) 's Twitter Profile Photo

Great to share the stage with the amazing Dr Neil Shore, longtime friend and Duke University alumni. We both had honor and pleasure to address the AEU AEU during on advanced pros Ca. My task was PARP inhibitors-three new FDA approvals just since last AUA!

Great to share the stage with the amazing Dr Neil Shore, longtime friend and @DukeU alumni. We both had honor and pleasure to address the AEU @InfoAeu during #AUA24 on advanced pros Ca. My task was PARP inhibitors-three new FDA approvals just since last AUA!
account_circle